DK0880970T3 - Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose - Google Patents

Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose

Info

Publication number
DK0880970T3
DK0880970T3 DK98104718T DK98104718T DK0880970T3 DK 0880970 T3 DK0880970 T3 DK 0880970T3 DK 98104718 T DK98104718 T DK 98104718T DK 98104718 T DK98104718 T DK 98104718T DK 0880970 T3 DK0880970 T3 DK 0880970T3
Authority
DK
Denmark
Prior art keywords
treatment
anticytokine
pharmaceutical compositions
disseminated sclerosis
disseminated
Prior art date
Application number
DK98104718T
Other languages
Danish (da)
English (en)
Inventor
David Wallach
Dan Aderka
Hartmut Engelmann
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0880970(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0880970T3 publication Critical patent/DK0880970T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK98104718T 1991-05-07 1992-05-07 Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose DK0880970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne
EP92107685A EP0512528B1 (fr) 1991-05-07 1992-05-07 Préparations pharmaceutiques contenant une anticytokine

Publications (1)

Publication Number Publication Date
DK0880970T3 true DK0880970T3 (da) 2006-11-20

Family

ID=11062415

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98104718T DK0880970T3 (da) 1991-05-07 1992-05-07 Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
DK92107685T DK0512528T3 (da) 1991-05-07 1992-05-07 Farmaceutisk præparat omfattende et cytokin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK92107685T DK0512528T3 (da) 1991-05-07 1992-05-07 Farmaceutisk præparat omfattende et cytokin

Country Status (12)

Country Link
EP (2) EP0512528B1 (fr)
JP (1) JP3320774B2 (fr)
AT (2) ATE334695T1 (fr)
AU (1) AU1609492A (fr)
CA (1) CA2068027C (fr)
DE (2) DE69229975T2 (fr)
DK (2) DK0880970T3 (fr)
ES (2) ES2137935T3 (fr)
GR (1) GR3031805T3 (fr)
IL (1) IL98078A0 (fr)
PT (1) PT880970E (fr)
ZA (1) ZA923310B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (fr) * 1989-04-21 2005-02-16 Amgen Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
ATE196849T1 (de) * 1993-07-30 2000-10-15 Kennedy Inst Of Rheumatology Verfahren zur behandlung von multiplesklerose
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
ATE212231T1 (de) 1995-07-14 2002-02-15 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
EP0942740B1 (fr) 1996-12-06 2003-08-27 Amgen Inc., Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
PT1471974E (pt) 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2511823A1 (fr) 2002-12-30 2004-07-22 Amgen Inc. Polytherapie a facteurs costimulants
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
SG11201607881SA (en) 2014-03-31 2016-10-28 Kirin Amgen Inc Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
EP0393438B1 (fr) * 1989-04-21 2005-02-16 Amgen Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
ATE119942T1 (de) * 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
ATE128184T1 (de) * 1989-12-13 1995-10-15 Yeda Res & Dev Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
RU2166955C2 (ru) * 1991-01-18 2001-05-20 Эмген Инк. Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0880970B1 (fr) 2006-08-02
PT880970E (pt) 2006-12-29
JPH05170661A (ja) 1993-07-09
DE69233643D1 (de) 2006-09-14
DE69229975T2 (de) 2000-05-11
EP0512528A3 (en) 1993-07-21
ATE184488T1 (de) 1999-10-15
JP3320774B2 (ja) 2002-09-03
ATE334695T1 (de) 2006-08-15
IL98078A0 (en) 1992-06-21
ZA923310B (en) 1993-01-27
CA2068027C (fr) 2003-09-23
GR3031805T3 (en) 2000-02-29
DK0512528T3 (da) 1999-12-20
ES2137935T3 (es) 2000-01-01
DE69233643T2 (de) 2007-07-26
EP0880970A1 (fr) 1998-12-02
EP0512528A2 (fr) 1992-11-11
AU1609492A (en) 1992-11-12
CA2068027A1 (fr) 1992-11-08
EP0512528B1 (fr) 1999-09-15
DE69229975D1 (de) 1999-10-21
ES2270479T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
FI944516A0 (fi) Fuusioproteiineja, jotka sisältävät kasvainkuoliotekijän reseptoria
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
EA200000311A1 (ru) Новый белок иммунной системы - кау
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
NL990033I1 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met dergelijk DNA.
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
ATE307204T1 (de) Tumor-nekrose-faktor ähnliches ligand
ES2130574T3 (es) Agentes de restriccion de las citoquinas.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
DE69533359D1 (de) Veränderte menschliche c3-proteine
DK1082131T3 (da) Immunoregulator
DK0553294T3 (da) Fremstillingen af sammensætninger til behandlingen af celleproliferationssygdomme
ES2142840T3 (es) Proteina que se une al interferon alfa/beta, su preparacion y las composiciones farmaceuticas que la contienen.
DE69803392D1 (de) Anti-cd40l immunotoxine zur behandlung von krankheiten
NO950420D0 (no) Interferon endelse derav
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
ZA9010036B (en) Expression of the recombinant tumor necrosis factor binding protein i(tbp-i)